Compare MVIS & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MVIS | PDSB |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0M | 42.4M |
| IPO Year | 2010 | 2015 |
| Metric | MVIS | PDSB |
|---|---|---|
| Price | $1.38 | $1.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 11.5M |
| Earning Date | 10-28-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.91 | ★ 28.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $664,000.00 | N/A |
| Revenue This Year | $1,017.55 | N/A |
| Revenue Next Year | $48.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.20 |
| 52 Week High | $4.90 | $1.79 |
| Indicator | MVIS | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 60.50 |
| Support Level | $0.56 | $0.60 |
| Resistance Level | $1.89 | $1.79 |
| Average True Range (ATR) | 0.11 | 0.22 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 67.05 | 60.67 |
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars. Geographically, the company operates in United States, Germany, and Other foreign countries.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.